研究者業績

永渕 泰雄

Yasuo Nagafuchi

基本情報

所属
自治医科大学 医学部内科学講座 アレルギー膠原病学部門 講師

研究者番号
20792279
ORCID ID
 https://orcid.org/0000-0002-1316-8035
J-GLOBAL ID
202501005738550204
researchmap会員ID
R000084374

研究キーワード

 3

論文

 59
  • Hirofumi Shoda, Yasuo Nagafuchi, Yumi Tsuchida, Keiichi Sakurai, Shuji Sumitomo, Keishi Fujio, Kazuhiko Yamamoto
    Arthritis research & therapy 19(1) 111-111 2017年5月31日  
    BACKGROUNDS: Obesity is associated with worse disease activity and drug responses in patients with rheumatoid arthritis (RA). However, the immunological mechanisms responsible for the relationship between RA and obesity have not yet been clarified in detail. This study aimed to elucidate the immunological mechanisms contributing to the pathogenesis of RA in overweight patients. METHODS: The frequencies of CD4+ T cell, B cell and monocyte subsets were analyzed in RA (n = 81) and healthy donors (n = 99) by flow cytometry, and were compared between three groups (body mass index (BMI) <20,  ≥20 to 25, >25). Serum cytokines were measured using multiplex ELISA. Gene expression was analyzed by quantitative PCR. Clinical information was extracted from medical records. RESULTS: The frequencies of T helper (Th)17 (CD4+CD45RA-CXCR5-CXCR3-CCR6+) cells and plasmablasts (PB) were significantly increased in patients with RA with BMI >25. Significant correlation was observed between BMI and Th17 cells in patients with RA. No significant differences in cell frequencies between the three BMI groups were observed in the healthy donors. Serum interleukin (IL)-1β and IL-21 significantly correlated with BMI in RA patients. Gene expression patterns in Th17 cells from overweight patients with RA showed the characteristics of pathogenic Th17 cells. CONCLUSIONS: Quantitative and qualitative changes in Th17 cells were characteristic in overweight patients with RA.
  • Shinichiro Nakachi, Shuji Sumitomo, Yumi Tsuchida, Haruka Tsuchiya, Masanori Kono, Rika Kato, Keiichi Sakurai, Norio Hanata, Yasuo Nagafuchi, Shoko Tateishi, Hiroko Kanda, Tomohisa Okamura, Kazuhiko Yamamoto, Keishi Fujio
    Arthritis research & therapy 19(1) 97-97 2017年5月16日  
    BACKGROUND: Regulatory T cells (Tregs) play a role in the suppression of inflammation in autoimmune diseases, and lymphocyte activation gene 3 (LAG3) was reported as a marker of interleukin (IL)-10-producing Tregs. We aimed to clarify the function of human IL-10-producing CD4+CD25-LAG3+ T cells (LAG3+ Tregs) and their association with rheumatoid arthritis (RA). METHODS: LAG3+ Tregs of human peripheral blood mononuclear cells (PBMCs) were cultured with B cells and follicular helper T cells to examine antibody suppression effects. The frequency of LAG3+ Tregs was evaluated in peripheral blood samples from 101 healthy donors and 85 patients with RA. In patients treated with abatacept, PBMC samples were analyzed before and after treatment. Naive CD4+ T cells were sorted and cultured in the presence of abatacept, followed by flow cytometric analysis and function assays. RESULTS: LAG3+ Tregs produced high amounts of IL-10 and interferon-γ, and they suppressed B-cell antibody production more strongly than CD25+ Tregs. Cell-to-cell contact was required for the suppressive function of LAG3+ Tregs. The frequency of LAG3+ Tregs was lower in patients with RA, especially those with higher Clinical Disease Activity Index scores. LAG3+ Tregs significantly increased after 6 months of abatacept treatment, whereas CD25+ Tregs generally decreased. Abatacept treatment in vitro conferred LAG3 and EGR2 expression on naive CD4+ T cells, and abatacept-treated CD4+ T cells exhibited suppressive activity. CONCLUSIONS: IL-10-producing LAG3+ Tregs are associated with the immunopathology and therapeutic response in RA. LAG3+ Tregs may participate in a mechanism for the anti-inflammatory and immune-modulating effects of targeted therapy for costimulation.
  • Yasuo Nagafuchi
    Scandinavian journal of rheumatology 2017年3月  
  • Mineto Ota, Yukiko Iwasaki, Hiroaki Harada, Oh Sasaki, Yasuo Nagafuchi, Shinichiro Nakachi, Shuji Sumitomo, Hirofumi Shoda, Shigeto Tohma, Keishi Fujio, Kazuhiko Yamamoto
    Modern rheumatology 27(1) 22-28 2017年1月  
    OBJECTIVES: Acute or subacute exacerbations are recognized as a severe complication of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Nevertheless, the role of intensive immunosuppression in RA-ILD remains elusive. We attempted to evaluate the clinical characteristics and efficacy of immunosuppressive treatment in exacerbated RA-ILD. METHODS: Clinical data, including respiratory function, imaging, treatment, and prognosis, were retrospectively collected for 17 patients with RA-ILD who required hospitalization at the University of Tokyo Hospital due to an acute exacerbation (12 patients) or subacute exacerbation (5 patients). RESULTS: Patients with RA-ILD demonstrated a significantly higher titers of anticyclic citrullinated peptide antibodies compared with RA patients in Japanese Ninja registry, suggesting the role of adaptive immunity. Immunosuppressive treatment suppressed the deterioration of pulmonary functions with improved ground grass opacity and consolidation. In particular, in patients with less fibrosis on computed tomography (CT) images showed a better response to treatment. Although five patients treated with combination therapy, including cyclophosphamide, showed a severely decreased lung volume, these intensive therapies provided a good prognosis without fatalities for the average observation period of 474 days. CONCLUSIONS: Immunosuppressive therapy is effective for exacerbations of RA-ILD. For severe cases with low respiratory function, intensive therapy, including cyclophosphamide, has a potential to improve the prognosis.
  • Yasuo Nagafuchi, Hirofumi Shoda, Shuji Sumitomo, Shinichiro Nakachi, Rika Kato, Yumi Tsuchida, Haruka Tsuchiya, Keiichi Sakurai, Norio Hanata, Shoko Tateishi, Hiroko Kanda, Keishi Fujio, Kazuhiko Yamamoto
    Clinical and experimental rheumatology 35(2) 354-355 2017年  
    ****************************************************************************.
  • Yasuo Nagafuchi, Hirofumi Shoda, Shuji Sumitomo, Shinichiro Nakachi, Rika Kato, Yumi Tsuchida, Haruka Tsuchiya, Keiichi Sakurai, Norio Hanata, Shoko Tateishi, Hiroko Kanda, Kazuyoshi Ishigaki, Yukinori Okada, Akari Suzuki, Yuta Kochi, Keishi Fujio, Kazuhiko Yamamoto
    Scientific reports 6 29338-29338 2016年7月7日  
    Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that leads to destructive arthritis. Although the HLA class II locus is the strongest genetic risk factor for rheumatoid arthritis, the relationship between HLA class II alleles and lymphocyte activation remains unclear. We performed immunophenotyping of peripheral blood mononuclear cells on 91 HLA-DRB1-genotyped RA patients and 110 healthy donors. The frequency of memory CXCR4(+)CD4(+) T cells, and not Th1 and Th17 cells, was significantly associated with disease severity by multiple linear regression analysis. RA patients with one or more susceptible HLA-DR haplotypes (shared epitope: SE) displayed a significantly higher frequency of memory CXCR4(+)CD4(+) T cells. Moreover, the frequency of memory CXCR4(+)CD4(+) T cells significantly correlated with the expression level of HLA-DR on B cells, which was elevated in RA patients with SE. In vitro analysis and transcriptomic pathway analysis suggested that the interaction between HLA-DR and T cell receptors is an important regulator of memory CXCR4(+)CD4(+) T cells. Clinically, a higher frequency of memory CXCR4(+)CD4(+) T cells predicted a better response to CTLA4-Ig. Memory CXCR4(+)CD4(+) T cells may serve as a powerful biomarker for unraveling the linkage between HLA-DRB1 genotype and disease activity in RA.
  • Hirofumi Shoda, Keishi Fujio, Keiichi Sakurai, Kazuyoshi Ishigaki, Yasuo Nagafuchi, Mihoko Shibuya, Shuji Sumitomo, Tomohisa Okamura, Kazuhiko Yamamoto
    Arthritis & rheumatology (Hoboken, N.J.) 67(5) 1171-81 2015年5月  
    OBJECTIVE: The balance between effector and regulatory CD4+ T cells plays a key role in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to examine whether the RA autoantigen BiP has epitopes for both effector and regulatory immunities. METHODS: The proliferation and cytokine secretion of peripheral blood mononuclear cells (PBMCs) from HLA-DR4-positive RA patients in response to BiP-derived peptides were examined by (3)H-thymidine uptake and enzyme-linked immunosorbent assay. As a mouse therapeutic model, a BiP-derived peptide was administered orally to mice with collagen-induced arthritis (CIA). RESULTS: Among the peptides examined, BiP(336-355) induced the strongest proliferation of PBMCs from RA patients, but not from healthy donors. The proliferation of PBMCs in response to BiP(336-355) showed a correlation with clinical RA activity and serum anti-BiP/citrullinated BiP antibodies. In contrast, BiP(456-475) induced interleukin-10 (IL-10) secretion from CD25-positive PBMCs obtained from RA patients and healthy donors without inducing cell proliferation, and it actively suppressed the BiP(336-355)-induced proliferation and proinflammatory cytokine secretion by PBMCs. Oral administration of BiP(456-475) to mice with CIA reduced the severity of arthritis and T cell proliferation and increased the secretion of IL-10 from T cells as well as the number of CD4+CD25+FoxP3+ regulatory T cells. CONCLUSION: Effector and regulatory T cells recognized different BiP epitopes. The deviated balance toward BiP-specific effector T cells in RA may be associated with disease activity; therefore, BiP-specific effector or regulatory T cells could be a target of new RA therapies.
  • Yasuo Nagafuchi, Hirofumi Shoda, Keishi Fujio, Satoru Ishii, Haruhito Sugiyama, Kazuhiko Yamamoto
    Modern rheumatology 23(5) 1013-7 2013年9月  
    A 28-year-old rheumatoid arthritis woman treated with adalimumab was admitted with fever, cough, and right chest pain. X-ray showed right pleural effusion. By medical thoracoscopy, diffuse white nodules were observed, and biopsy specimen demonstrated epithelioid cell granulomas with necrosis and auramine-stained organisms, which suggested a diagnosis of tuberculous pleurisy. Medical thoracoscopy can be a potent diagnostic method when tuberculous pleurisy is suspected. Notably, despite latent tuberculosis treatment, active tuberculosis was not prevented.
  • Yasuo Nagafuchi, Shuji Sumitomo, Yoko Soroida, Takeyuki Kanzaki, Yukiko Iwasaki, Kazuya Michishita, Tomomi Iwai, Hitoshi Ikeda, Keishi Fujio, Kazuhiko Yamamoto
    Annals of the rheumatic diseases 72(7) 1267-9 2013年7月  

主要なMISC

 111

共同研究・競争的資金等の研究課題

 3